Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies.
Immunocore has raised €252M across 2 funding rounds from 2 investors, most recently a Debt round in Feb 2021. Based in Abingdon, UK; founded 2008; active in Healthtech. Data as of 6 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2021-02-05 | Debt | €190M | Oxford Finance LLC | View deal → |
| 2021-01-13 | Series C | €62M | BlackRock | View deal → |
